produced by cancer cells). Further understanding of the immune-resistant pkchanisms, which may be possible through comparative analyses of responders and non-responders to the immunotherapies, will lead to the identification of new diagnostic biomarkers and therapeutic targets for developpknt of eklective cancer immuno therapies.The immunological background for the process of tumor growth is still oadcure. However, our understanding of what happens could